Lantern Pharma (LTRN) has issued an announcement.
On August 8, 2024, the Company is set to host a conference call and live webinar to discuss its second-quarter financial and operational results, as well as to present details regarding the LP-300 product candidate and its Harmonic™ Phase 2 clinical trial. These discussions aim to provide a comprehensive update to stakeholders and interested parties regarding the company’s recent performance and ongoing research developments.
Learn more about LTRN stock on TipRanks’ Stock Analysis page.
